An observational study emulated a target trial to determine the risk for major adverse cardiovascular events (MACE) and fracture prevention effects with denosumab versus bisphosphonates in dialysis-dependent patients.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
